Two more generic semaglutide products approved in Canada but not yet on shelves

Health Canada's Drug Product Database lists Aspen-Semaglutide and Sevmia as approved, with no market date for either as of July 28, 2026 ^[1]. Both are generic versions of semaglutide, the molecule sold as Ozempic, Wegovy and Rybelsus. An approved entry in the database does not mean a product can be bought at a pharmacy counter ^[1].

Health Canada tracks approval and marketing as separate stages, and the listing for each of the two products carried no date on which sales would begin ^[1]. Health Canada has now approved three of nine generic semaglutide products, according to a running count of the Canadian market ^[1]. The generic that has reached patients is Dr. Reddy's, which received its authorization on April 28 and whose product reached Canadian pharmacies in 2026 ^[1].

Moving from approval to shelves involves supply and money. How quickly a generic semaglutide becomes available turns on manufacturing capacity and on pricing and listing decisions that are settled after authorization ^[1]. Canada's pan-Canadian pricing framework sets the first generic semaglutide entrant at 75% to 85% of the brand price, with the benchmark dropping to 35% once three or more generics reach the market ^[1]. A 65% list-price cut for Canadian benefits plans is tied to the arrival of a third generic ^[1]. Those lower tiers are not in play for products that are approved but not yet sold.

No market date for Aspen-Semaglutide or Sevmia has been disclosed ^[1].

Why it matters for patients

This is a Canadian regulatory step. It does not change which semaglutide products are sold at US pharmacies or what US insurers cover, and no US generic version of semaglutide is part of this development.

For people watching semaglutide prices, the milestone that matters is marketing, not approval. A market date, along with provincial listing and pricing decisions, is what puts a product within reach of a pharmacy counter, and none of that has been reported for the two newly approved products ^[1].

Generic entry also lowers prices in steps rather than all at once. One generic on the market produces a discount off the brand price; the deeper cut is tied to a third entrant ^[1]. Two approved-but-unmarketed products do not count toward that threshold while they are not being sold.

The development concerns semaglutide only. It does not apply to tirzepatide (Mounjaro, Zepbound) or orforglipron (Foundayo), which are different molecules.

What happens next

• No market date for Aspen-Semaglutide or Sevmia has been disclosed ^[1].
• Sandoz has been reported as targeting the third quarter of 2026 for its generic semaglutide, and Aspen has been described as going to Canada first ^[1].
• Additional generic semaglutide submissions are still under review at Health Canada ^[1].